Norihiro Kogame

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/346920/publications.pdf

Version: 2024-02-01

516710 345221 45 1,422 16 36 citations g-index h-index papers 45 45 45 1769 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Diagnostic concordance and discordance between angiography-based quantitative flow ratio and fractional flow reserve derived from computed tomography in complex coronary artery disease. Journal of Cardiovascular Computed Tomography, 2022, 16, 336-342.	1.3	5
2	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drugâ€Eluting Stent Implantation: Perâ€Protocol Analysis of the GLOBAL LEADERS Trial. Journal of the American Heart Association, 2022, 11, e024291.	3.7	4
3	Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS Trial. Canadian Journal of Cardiology, 2021, 37, 122-130.	1.7	4
4	A Prospective Multicenter Randomized Trial to Assess the Effectiveness of the MagicTouch Sirolimus-Coated Balloon in Small Vessels: Rationale and Design of the TRANSFORM I Trial. Cardiovascular Revascularization Medicine, 2021, 25, 29-35.	0.8	10
5	Predicting 2â€year allâ€cause mortality after contemporary <scp>PCI</scp> : Updating the logistic clinical <scp>SYNTAX</scp> score. Catheterization and Cardiovascular Interventions, 2021, 98, 1287-1297.	1.7	6
6	Impact of stent length and diameter on 10â€year mortality in the <scp>SYNTAXES</scp> trial. Catheterization and Cardiovascular Interventions, 2021, 98, E379-E387.	1.7	10
7	A prospective multicenter validation study for a novel angiography-derived physiological assessment software: Rationale and design of the radiographic imaging validation and evaluation for Angio-iFR (ReVEAL iFR) study. American Heart Journal, 2021, 239, 19-26.	2.7	4
8	Two years clinical outcomes with the stateâ€ofâ€theâ€art PCI for the treatment of bifurcation lesions: A subâ€analysis of the SYNTAX II study. Catheterization and Cardiovascular Interventions, 2020, 96, 10-17.	1.7	1
9	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention. JAMA Cardiology, 2020, 5, 21.	6.1	49
10	Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS. Canadian Journal of Cardiology, 2020, 36, 747-755.	1.7	2
11	Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 222-230.	3.0	7
12	Cracking (the code of) coronary artery calcification to win the last battle of percutaneous coronary intervention: still in the middle of a rocky road. European Heart Journal, 2020, 41, 797-800.	2.2	3
13	Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. Catheterization and Cardiovascular Interventions, 2020, 96, 1369-1378.	1.7	6
14	The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy. International Journal of Cardiovascular Imaging, 2020, 36, 565-575.	1.5	O
15	Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. Clinical Research in Cardiology, 2020, 109, 918-929.	3.3	3
16	Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 22-30.	3.0	7
17	Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD. JACC: Cardiovascular Interventions, 2020, 13, 2251-2262.	2.9	70
18	A Randomized Trial Evaluating Online 3-Dimensional Optical Frequency Domain Imaging–Guided Percutaneous Coronary Intervention in Bifurcation Lesions. Circulation: Cardiovascular Interventions, 2020, 13, e009183.	3.9	19

#	Article	IF	CITATIONS
19	The Impact of Coronary Physiology on Contemporary Clinical Decision Making. JACC: Cardiovascular Interventions, 2020, 13, 1617-1638.	2.9	60
20	Advances in IVUS/OCT and Future Clinical Perspective of Novel Hybrid Catheter System in Coronary Imaging. Frontiers in Cardiovascular Medicine, 2020, 7, 119.	2.4	65
21	Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006660.	2.2	11
22	Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e009177.	3.9	15
23	Drug-eluting bioresorbable scaffolds in cardiovascular disease, peripheral artery and gastrointestinal fields: a clinical update. Expert Opinion on Drug Delivery, 2020, 17, 931-945.	5.0	6
24	Final 3-Year Outcomes of MiStent Biodegradable Polymer Crystalline Sirolimus-Eluting Stent Versus Xience Permanent Polymer Everolimus-Eluting Stent. Circulation: Cardiovascular Interventions, 2020, 13, e008737.	3.9	17
25	DAPT Score and the Impact of TicagrelorÂMonotherapy During the Second Year After PCI. JACC: Cardiovascular Interventions, 2020, 13, 634-646.	2.9	17
26	Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. Atherosclerosis, 2020, 295, 45-53.	0.8	36
27	Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. Clinical Research in Cardiology, 2020, 109, 930-943.	3.3	14
28	The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: Results from a 2-year follow-up of the GLOBAL LEADERS trial. Atherosclerosis, 2020, 303, 1-7.	0.8	1
29	Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2020, 96, E516-E526.	1.7	5
30	The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. Clinical Research in Cardiology, 2020, 109, 1125-1139.	3.3	14
31	Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial. EuroIntervention, 2020, 16, 634-644.	3.2	6
32	Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. European Heart Journal, 2019, 40, 2595-2604.	2.2	93
33	Efficacy and Safety of TicagrelorÂMonotherapy in PatientsÂUndergoing Multivessel PCI. Journal of the American College of Cardiology, 2019, 74, 2015-2027.	2.8	23
34	Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial). American Journal of Cardiology, 2019, 124, 1833-1840.	1.6	5
35	Clinical Implication of Quantitative Flow Ratio After Percutaneous Coronary Intervention for 3-Vessel Disease. JACC: Cardiovascular Interventions, 2019, 12, 2064-2075.	2.9	71
36	Impact of postâ€procedural minimal stent area on 2â€year clinical outcomes in the SYNTAX II trial. Catheterization and Cardiovascular Interventions, 2019, 93, E225-E234.	1.7	26

#	Article	IF	CITATIONS
37	Mechanical properties and performances of contemporary drug-eluting stent: focus on the metallic backbone. Expert Review of Medical Devices, 2019, 16, 211-228.	2.8	27
38	Serial Optical Coherence Tomography at Baseline, 7 Days, and 1, 3, 6 and 12 Months After Bioresorbable Scaffold Implantation in a Growing Porcine Model. Circulation Journal, 2019, 83, 556-566.	1.6	1
39	Angiography-Derived Fractional Flow Reserve in the SYNTAX II Trial. JACC: Cardiovascular Interventions, 2019, 12, 259-270.	2.9	46
40	Contemporary Outcomes Following Coronary Artery Bypass Graft Surgery forÂLeftÂMainÂDisease. Journal of the American College of Cardiology, 2019, 73, 1877-1886.	2.8	33
41	Feasibility of planning coronary artery bypass grafting based only on coronary computed tomography angiography and CT-derived fractional flow reserve: a pilot survey of the surgeons involved in the randomized SYNTAX III Revolution trial. Interactive Cardiovascular and Thoracic Surgery, 2019, 29, 209-216.	1.1	24
42	The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial. International Journal of Cardiovascular Imaging, 2019, 35, 1189-1198.	1.5	6
43	Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. International Journal of Cardiology, 2019, 286, 43-50.	1.7	19
44	Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial. EuroIntervention, 2019, 15, e1090-e1098.	3.2	16
45	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet, The. 2018. 392. 940-949.	13.7	555